New York based life science PE group Aisling Capital is saving the labrats and entrepreneurs! The firm just closed on a $650M fund to invest in pharmaceutical, biopharmaceutical, medical products, manufacturing and service companies. And who says there’s a recession? Remember – it’s who you are and who you know.

What did senior partner Dennis Purcell have to say anyway:

“We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence. We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor.”

Good for them. Now all you labrats and early-mid stage companies - get a few sheets from the roll!

Image from baronbob

Related Posts